Published by
The Street
The Street
By GlobeNewswire – Growing body of evidence validates Vir’s approach of targeting a highly conserved region of the spike protein – – Together with recent pseudo- and live virus results, additional preclinical data reinforce sotrovimab retains in vitro neutralizing activity against all known variants of concern, including the highly divergent Omicron variant – SAN FRANCISCO, Dec. 31, 2021 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new preclinical research published to the preprint server bioRxiv, describing the structural basis and magnitude by which the new SAR…